文献速递艾滋病与性传播感染

AS01B佐剂在ALVAC-HIV(vCP2438)联合佐剂二价C亚型gp120随机预防性HIV疫苗试验中的蛋白剂量节省效应

Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120.
PubMed 文献 · J Infect Dis · 2024-01-01

HVTN 120是一项1/2a期随机双盲安慰剂对照HIV疫苗试验,在160名健康HIV未感染者中评估ALVAC-HIV(vCP2438)联合MF59或AS01B佐剂二价C亚型gp120 Env蛋白两种剂量水平的安全性和免疫原性。结果显示疫苗总体安全耐受,40 μg gp120/AS01B方案诱导的CD4+ T细胞和结合抗体应答最高。

要点

  • AS01B佐剂组在6.5和12个月时CD4+ T细胞应答率和幅度高于MF59佐剂组
  • 12个月时40 μg gp120/AS01B组Env-gp120结合抗体应答幅度高于两个200 μg gp120组
  • 40 μg gp120/AS01B方案诱导的CD4+ T细胞和结合抗体应答最高

核心结论

  • 40 μg剂量gp120/AS01B方案诱导的CD4+ T细胞和结合抗体应答最高。

研究设计与样本

  • HVTN 120是一项1/2a期随机双盲安慰剂对照HIV疫苗试验,在健康HIV未感染者中评估ALVAC-HIV(vCP2438)联合MF59或AS01B佐剂二价C亚型gp120 Env蛋白两种剂量水平的安全性和免疫原性。
  • 共纳入160名参与者,55%为女性,年龄18-40岁(中位年龄24岁),其中150人接种疫苗、10人接种安慰剂。

主要发现

  • 疫苗总体安全且耐受良好。
  • 第6.5和12个月时,AS01B佐剂组的CD4+ T细胞应答率和幅度高于MF59佐剂组。
  • 第12个月时,40 μg gp120/AS01B组的HIV特异性Env-gp120结合抗体应答幅度高于两个200 μg gp120组。

关键数值与推荐

  • 参与者在第0和1个月单独接种ALVAC-HIV(vCP2438)或安慰剂。
  • 第3和6个月,参与者分别接种安慰剂、ALVAC-HIV(vCP2438)联合200 μg MF59或AS01B佐剂二价C亚型gp120,或ALVAC-HIV(vCP2438)联合40 μg AS01B佐剂二价C亚型gp120。
  • 主要结局为安全性和免疫应答。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: HVTN 120 is a phase 1/2a randomized double-blind placebo-controlled human immunodeficiency virus (HIV) vaccine trial that evaluated the safety and immunogenicity of ALVAC-HIV (vCP2438) and MF59- or AS01B-adjuvanted bivalent subtype C gp120 Env protein at 2 dose levels in healthy HIV-uninfected adults. METHODS: Participants received ALVAC-HIV (vCP2438) alone or placebo at months 0 and 1. At months 3 and 6, participants received either placebo, ALVAC-HIV (vCP2438) with 200 μg of bivalent subtype C gp120 adjuvanted with MF59 or AS01B, or ALVAC-HIV (vCP2438) with 40 μg of bivalent subtype C gp120 adjuvanted with AS01B. Primary outcomes were safety and immune responses. RESULTS: We enrolled 160 participants, 55% women, 18-40 years old (median age 24 years) of whom 150 received vaccine and 10 placebo. Vaccines were generally safe and well tolerated. At months 6.5 and 12, CD4+ T-cell response rates and magnitudes were higher in the AS01B-adjuvanted groups than in the MF59-adjuvanted group. At month 12, HIV-specific Env-gp120 binding antibody response magnitudes in the 40 μg gp120/AS01B group were higher than in either of the 200 μg gp120 groups. CONCLUSIONS: The 40 μg dose gp120/AS01B regimen elicited the highest CD4+ T-cell and binding antibody responses. Clinical Trials Registration . NCT03122223.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Chirenje ZM, Laher F, Dintwe O, et al. Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120. J Infect Dis. 2024. PMID: 37795976. doi:10.1093/infdis/jiad434

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。